CONNEQT, a subsidiary of CardieX, introduces an innovative medical device named CONNEQT Pulse, marking a significant breakthrough in healthcare.
This cutting-edge vascular biometric dual blood pressure monitor is the world's first of its kind, capable of measuring both brachial and central blood pressures and analyzing arterial waveforms.
Powered by CardieX's patented SphygmoCor® technology, the CONNEQT Pulse provides individuals with valuable insights into their heart health that were previously only accessible in specialized medical settings.
This groundbreaking device allows users to access vital arterial health indicators, including brachial blood pressure, central blood pressure, augmentation index, and various clinically relevant digital vascular biomarkers.
What sets the CONNEQT Pulse apart is its ability to offer a comprehensive and precise assessment of vascular health, surpassing traditional brachial home blood pressure monitors.
By utilizing pulse wave analysis technologies similar to those employed by cardiologists in clinical environments, the Pulse accurately predicts pressure near the aorta.
In addition to measuring central and brachial blood pressures, the CONNEQT Pulse analyzes five essential digital vascular biomarkers, enabling remote tracking of subendocardial viability ratio, heart rate, central pulse pressure, augmentation pressure, and augmentation index.
This remote monitoring capability eliminates the need for patients to visit medical facilities and is particularly advantageous for decentralized clinical trials, reducing the risk of white coat hypertension and enabling convenient home-based monitoring.
The CONNEQT Pulse is available by prescription for hypertensive patients who require regular monitoring of their heart health. Its user-friendly interface empowers individuals to regularly track their blood pressure and other biomarkers, taking control of their cardiovascular well-being.
Measurement data is seamlessly transmitted wirelessly to the CONNEQT Patient Management Portal, a secure and HIPAA-compliant cloud-based database, enabling physicians to remotelym access their patient's arterial health indicators.
The Pulse's software is highly customizable, allowing both physicians and patients to select the parameters displayed on the device and personalize their screens based on individual health needs. This personalized and comprehensive range of cardiovascular information distinguishes the Pulse as the first home blood pressure monitor to provide tailored insights to users.
For instance, individuals at risk of developing Alzheimer's disease can prioritize the display of central pulse pressure and the augmentation index, crucial indicators affecting brain health.
The CONNEQT Pulse is expected to be commercially available in the third quarter of this year, revolutionizing at-home monitoring and empowering individuals to proactively manage their cardiovascular health.
